Document text
Principal Investigator: Feng Guo
Organization: UNIVERSITY OF CALIFORNIA LOS ANGELES
Fiscal Year: 2024
Award: $478,737
Funding agency: National Institute of Allergy and Infectious Diseases
Project Summary (Abstract)
Developing three-dimensional antisense oligonucleotide drugs against COVID-19
The culprit of coronavirus disease 2019 (COVID-19) pandemic, severe acute respiratory syndrome-related
coronavirus-2 (SARS-CoV-2), has a very large RNA genome that encodes the proteins and RNA elements
required for all aspects of viral infection and replication. This property makes the virus vulnerable to a new class
of drugs called antisense oligonucleotide (ASO). ASOs are single-stranded synthetic nucleic acids that achieve
therapeutic effects by binding to viral or other target RNAs via Watson-Crick base pairing, the very interaction
that defines molecular biology and the foundation of life. The first ASO drug approved by the U.S. Food and Drug
Administration is an antiviral against cytomegalovirus. A major challenge of developing ASO antiviral drugs is
the strong tendency of RNA to fold into structures that interfere with ASO hybridization. Current ASO design
methods do not adequately address this problem.
We have developed a structure-based ASO design technology platform that takes advantage of three-
dimensional structures of target RNAs. Our “3D-ASOs” recognize not only the sequences but also the shapes of
SARS-CoV-2 RNAs. Compared to conventional designs, 3D-ASOs contact viral RNAs more extensively and
therefore can achieve greater affinity and specificity. Our technology platform includes four design templates and
a 3D-ASO drug development workflow that employs an innovative RNA structure determination method. In a
preliminary study, we designed and tested several 3D-ASOs against SARS-CoV-2 viral RNA and identified two
lead sequences that strongly inhibit viral replication in cultured human cells to a much greater extent than
previously reported sequences. In the proposed research, we will optimize the lead 3D-ASOs by altering their
backbone modifications and bases for tighter binding and better fit to the viral RNAs and for stronger inhibition
to their functions. We will also cast our net wide by designing and testing additional anti-SARS-CoV-2 3D-ASOs.
Finally, the most potent 3D-ASOs will be tested in an animal model. If successful, the project will provide ASO
drug candidates for clinical trials. These drugs may be given as nasal sprays or via intravenous injection, as
treatments or for prevention. The structure-based design technology we will refine is generally applicable to ASO
drug development. Therefore, this research has the potential to turn tide on the battlefield against COVID-19 and
in our fight with many other diseases.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><3-D><3-D structure><3-Dimensional><3-dimensional structure><3D><3D structure><ASO therapeutics><ASO therapy><ASO treatment><Academia><Address><Affect><Affinity><Algorithms><Animal Model><Animal Models and Related Studies><Anti-viral Agents><Antisense Agent><Antisense Oligonucleotide Therapy><Antisense Oligonucleotides><Base Pairing><Binding><Biochemical><Biological><CMV><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 period><COVID-19 public health crisis><COVID-19 therapy><COVID-19 treatment><COVID-19 virus><COVID-19 years><COVID19 virus><CV-19><Cell Body><Cells><Cessation of life><Chemicals><Clinical Trials><CoV-2><CoV2><Communicable Diseases><Complex><Coronavirus Infectious Disease 2019><Cytomegalovirus><DNA Molecular Biology><Data><Death><Development><Disease><Disorder><Drug resistant viral><Drugs><Elements><Emergencies><Emergency Situation><Emerging Communicable Diseases><Emerging Infectious Diseases><Feedback><Food and Drug Administration><Formulation><Foundations><Free Energy><GS-5734><Gene Transcription><Genetic Alteration><Genetic Change><Genetic Transcription><Genetic defect><Genome><Goals><H-bond><HCMV><Human><Hydrogen Bonding><Industry><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Lead><Life><Literature><Medication><Methods><Mice><Mice Mammals><Modern Man><Modification><Molecular Biology><Molecular Interaction><Monitor><Murine><Mus><Mutation><Nasal><Nasal Passages Nose><Non-Polyadenylated RNA><Nose><Nucleic Acids><Oligo><Oligonucleotides><Pathogenicity><Pattern><Pb element><Persons><Pharmaceutical Preparations><Phylogenetic Analysis><Phylogenetics><Predisposition><Prevention><Production><Program Development><Property><Proteins><RNA><RNA Expression><RNA Gene Products><RNA Viruses><Reporting><Research><Respiratory System, Nose, Nasal Passages><Ribonucleic Acid><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 inhibitor><SARS-CoV-2 pandemic><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Salivary Gland Viruses><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 inhibitor><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><Shapes><Site><Specificity><Spinal Column><Spine><Structure><Susceptibility><Symptoms><Technology><Testing><Therapeutic Effect><Transcription><USFDA><United States Food and Drug Administration><Vaccines><Veklury><Vertebral column><Viral><Viral Diseases><Virus><Virus Diseases><Virus Replication><Wuhan coronavirus><access to health care><access to healthcare><accessibility of health care><accessibility to health care><accessibility to healthcare><anti-sense oligonucleotide drug><anti-sense oligonucleotide therapy><anti-sense oligonucleotide treatment><anti-sense therapy><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><antisense drug><antisense oligo><antisense oligonucleotide therapeutic><antisense therapeutics><antisense therapy><backbone><base><bases><biologic><block SARS-CoV-2><block severe acute respiratory syndrome coronavirus 2><clinical candidate><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 virus><coronavirus infectious disease-19><cytomegalovirus group><design><designing><developmental><drug candidate><drug development><drug resistant virus><drug/agent><fighting><genome mutation><hCoV19><health care access><health care availability><health care service access><health care service availability><healthcare access><healthcare accessibility><healthcare availability><healthcare service access><healthcare service availability><heavy metal Pb><heavy metal lead><high risk><improved><in vivo><inhibit SARS-CoV-2><inhibit severe acute respiratory syndrome coronavirus 2><innovate><innovation><innovative><innovative technologies><intravenous injection><lead optimization><model of animal><mouse model><murine model><nCoV2><new drug class><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel drug class><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><oligos><pandemic><pandemic disease><prevent><preventing><remdesivir><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><synthetic nucleic acid><technology platform><technology system><three dimensional><three dimensional structure><treat COVID-19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><viral RNA><viral infection><viral multiplication><viral replication><virus RNA><virus infection><virus multiplication><virus-induced disease>